SCD1

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Retrieved on: 
Friday, March 15, 2024
Cirrhosis, BID, Aramchol, SCD1, Fibrosis, Patent, NASH, Liver, TEL

With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until September 2039.

Key Points: 
  • With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until September 2039.
  • Previously, Galmed reported results from the Open-Label part of its Phase 3 NASH study, which demonstrated that treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement.
  • Mr. Baharaff continued "It is clear today that NASH is a chronic condition with multiple liver pathologies.
  • By combining Aramchol and Resmetirom, two distinct and selective compounds with complementary mechanisms, we believe this will provide a perfect treatment for NASH."

The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights

Retrieved on: 
Tuesday, May 23, 2023
Lipotoxicity, Insulin resistance, Madrigal, FXR, Fibrosis, Obesity, NASH, Novo Nordisk, Diabetes, Liver disease, Obeticholic acid, Cardiovascular disease, Weight loss, Intercept Pharmaceuticals, NDA, History, Type 2 diabetes, Gastroenterology, GLP1, SCD1, FGF21, Inflammation, Hypertension, Hyperlipidemia, Incidence, Metabolism, Patient, Metabolic syndrome, Physician, OCA, Cirrhosis, ICER, NAFLD, Bariatric surgery, FDA, Therapy, Hepatitis, Pharmaceutical industry, Nursing

EXTON, Pa., May 22, 2023 /PRNewswire/ -- The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S. Despite the significant size and unmet need of the potential market, pharmaceutical companies have yet to capitalize on the opportunity.  

Key Points: 
  • Despite the significant size and unmet need of the potential market, pharmaceutical companies have yet to capitalize on the opportunity.
  • Both resmetirom and OCA are being evaluated in NASH patients with confirmed liver fibrosis.
  • Insights from Spherix's Market Dynamix™ NAFLD/NASH service highlight reducing liver fibrosis is currently the highest priority for gastroenterologists.
  • The road to achieving life changing treatment for NAFLD/NASH is long and fraught with difficulty, but for the companies committed to helping these patients, opportunities abound.

Gastric Cancer Foundation Invites U.S. Researchers to Apply for Early-Stage Grant Funding

Retrieved on: 
Tuesday, March 7, 2023
Dana–Farber Cancer Institute, SAN, Stomach, Research, Vanderbilt University Medical Center, Chairperson, Cancer, Disease, SCD1, Letter, PARP, Organization, GCF, Pharmaceutical industry

SAN MATEO, Calif., March 7, 2023 /PRNewswire-PRWeb/ -- The Gastric Cancer Foundation (GCF) is pleased to announce the expansion of its early-stage research program and launch of its 2023 application process. GCF plans to award up to $300,000 in grant funding—increased from $200,000 in recent years—and is now accepting letters of intent from researchers in the United States who are working on novel projects aimed at discovering new therapies for this challenging disease.

Key Points: 
  • The objective of GCF's grant program is to support new research projects centered around discovering novel therapies or treatment regimens for gastric cancer.
  • Researchers who are interested in applying for a grant should email a letter of intent by March 31 to [email protected] .
  • The Gastric Cancer Foundation's grant program, now in its fifth year, is part of GCF's overall mission to expand research.
  • The Foundation has granted more than $1.2 million in seed grants for gastric cancer research, providing much needed support for this cancer that receives less than 1% of all federal funding for cancer research.

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Retrieved on: 
Thursday, July 7, 2022
TEL, Ulcerative colitis, Liver, IPF, Tissue, Bleomycin, CPA, Inflammation, Hydroxyproline, Immunohistochemistry, DSS, SCD1, IBD, Lung, Fibrosis, Gold, Inflammatory bowel disease, Pulmonary fibrosis, Pharmaceutical industry, Pirfenidone

TEL AVIV, Israel, July 7, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases, announced today results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal (GI) fibrosis.

Key Points: 
  • TEL AVIV, Israel, July 7, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases, announced today results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal (GI) fibrosis.
  • To date, only limited anti-fibrotic drugs are approved or are in development, most of which have restricting side effects.
  • Treatment with Aramchol resulted in statistically significant fibrosis improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone which is the gold standard treatment.
  • Statistically significant improvements were also demonstrated in a validated DSS model of inflammatory bowel disease (IBD).

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Retrieved on: 
Monday, October 11, 2021
Forward-looking statement, Arrest & Trial, Patient, Inflammation, Cirrhosis, Publication, Hebrew University of Jerusalem, TEL, Eleazar Sukenik, Non-alcoholic fatty liver disease, Liver, COVID-19, SCD, Physician, Manuscript, Drug development, Safety, PK, Population, Annual report, SEC, Kinetics, Terminology, ARMOR, FDA, Steatosis, Perception, Hepatocyte, EMA, Liver cancer, SCD1, AMPK, Hepatic stellate cell, Fatty liver disease, Clinical trial, Cardiovascular disease, Obesity, Risk, NASH, Mall of America, Pharmaceutical industry, Dietary supplement

TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).

Key Points: 
  • TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).
  • The ARREST Phase 2b study randomized 247 patients with NASH confirmed by liver biopsy.
  • Data from the ARREST Phase 2b study published in this paper demonstrate how the mechanism of action of Aramchol translates into clinical performance.
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.